Royalty Report: Drugs, Biotechnology, Therapeutic – Collection: 3851

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Biotechnology
  • Therapeutic
  • Pharmaceuticals
  • Diagnostic
  • HPV

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 3851

License Grant
The Licensor granted the Licensee an exclusive, worldwide and non-assignable except as specified license under the invention to test, evaluate and develop  the Licensed Products in the Field of Use.
License Property
Licensed Products shall mean monoclonal antibodies or treatments derived from the invention.

An employee of the Licensor, is the inventor who has submitted the following disclosures, a portion of which constitute the Invention  (i) UA1524, Therapeutic Monoclonal IgA Antibodies to Cryptosporidium Antigens of 500KDa and Less Than 1,000KDa; (ii) UA1525, Anti-GP23 Antigen Monoclonal IgA Antibodies for Treatment of Cryptosporidiosis, G9H4 and H8H2 and (iii) UA1526, Monoclonal IgA Antibody 1B8 Directed to Cryptosporidium 200KDa Antigen.

Field of Use
Field of Use shall mean the use of the invention for regulator-approved human therapeutics in the treatment of Cryptosporidiosis in humans.

IPSCIO Record ID: 29179

License Grant
The Licensor granted an exclusive, worldwide and non-assignable except as herein specified License under the invention to test, evaluate and develop the Licensed Products in the Field of Use.

An employee of the Licensor is the Inventor who has submitted a disclosure  Monoclonal Antibodies Reactive with Multiple Neutralization-Sensitive Surface Epitopes as a Source of Treatment of Enteric Cryptosporidiosis.

Field of Use
The Field of used shall mean the use of Invention for Regulator-approved human therapeutics in the treatment of cryptosporidiosis in patients with Acquired Immune Deficiency Syndrome (AIDS) and in certain immune competent human patients.

IPSCIO Record ID: 29180

License Grant
The Licensor granted an exclusive, worldwide, non-assignable License for the invention, to test, evaluate, and develop licensed products in the field of use.

Employees of the Licensor are the inventors of  Anti-Cryptosporidium parvum Sporozoite IgA Monoclonal Antibody.

Field of Use
Field of use shall mean the use of the invention for regulator approved human therapeutics in the treatment of cryptosporidiosis in patients with Acquired Immune Deficiency Syndrome (AIDS) and in certain immune compromised patients.

IPSCIO Record ID: 29178

License Grant
The Licensor granted an exclusive, worldwide, and non-assignable except as specified License under the Invention to test, evaluate, and develop the Licensed products.

Licensed Products shall mean hyperimmune hen egg yolks containing Anti-Cryptosporidium antibodies derived from the Invention. The employees of the Licensee, are The Inventors who have disclosed an invention, Hyperimmune Egg Yolks as a Source of Anti-Cryptosporidium Neutralizing Antibodies Suitable for Passive Immune.

Field of Use
Field of use shall mean the use of invention for regulator approved  human therapeutics in the treatment of cryptosporidiosis in patients with Acquired Immune Deficiency Syndrome (AIDS) and in certain immune competent patients.

IPSCIO Record ID: 29176

License Grant
The University granted the an exclusive, worldwide and non-assignable except as specified license under the Invention to test, evaluate and develop the Licensed Product(s) in the Field of Use.
License Property
An employee of the Licensor has submitted a disclosure entitled “Treatment and Prevention of Helicobacter Pylori Infection with Hyperimmune Hen Egg Yolk Antibodies”.
Field of Use
Field of Use shall mean the use of Invention for Regulator approved human therapeutics in the treatment of Helicobacter Pylori.

IPSCIO Record ID: 29177

License Grant
Licensor granted the Licensee an exclusive, worldwide and non-assignable except as specified license under the Invention to test, evaluate and develop the Licensed Product(s) in the Field of Use.
License Property
The employees of the Licensor, have submitted a disclosure entitled Hen Yolk Antibodies to Clostridium Difficile and Methods of Use.
Field of Use
Field of Use shall mean the use of Invention for Regulator approved human therapeutics in the treatment of Clostridium Difficile.

IPSCIO Record ID: 6244

License Grant
The Licensor granted the Argentinian Licensee. an exclusive license for Mexico and all the countries of Central America and South America, with the exception of Brazil, for the products. Products mean finished pharmaceutical products for the indications of Cryptosporidium parvum and Clostridium difficile infections using the BAI as active substance.

Licensor wishes to provide Licensee, with the technology and all other information and know how related to the treatment of Cryptosporidium parvum and Clostridium difficile infections in order to enable Licensee to manufacture finished pharmaceutical products with said indications.

License Property
The License also includes a Patent related to the Treatment of Intestinal Parasitosis by Enteral Administration of Hen Egg Yolk Antibodies, namely US Patent 5,753,228, covering a method for treating Cryptosporidium parvum.
Field of Use
Cryptosporidium parvum is one of several species that cause cryptosporidiosis, a parasitic disease of the mammalian intestinal tract.

IPSCIO Record ID: 1395

License Grant
Licensor hereby grants, and Licensee hereby accepts, the following licenses

(a) an exclusive, worldwide license, including the right to grant sublicenses, to develop, make, have made, import, use, sell, offer to sell or have sold Licensed Products and related cell lines, including the Sp2/0 Cell Line.

License Property
Licensor has developed a murine monoclonal antibody directed against the CCR5 antigen and designated by Licensee's as “PRO 140”

“Humanized Antibody(ies)” means the humanized form of the Murine Antibody.

“Licensed Product(s)” means products, for any use, incorporating substantially all of the Humanized Antibody or any modification, variant or fragment of the Humanized Antibody containing at least one variable region of the Humanized Antibody.

“Murine Antibody(ies)” means, subject to Section 2.01(b), the murine monoclonal antibody designated as “PRO 140” directed against the Target Antigen.

Field of Use
Licensee shall also evaluate the Humanized Antibody to determine whether such antibody also possesses anti-HIV activity not less than one-third (1/3) that of the Murine Antibody (“Minimum Anti-HIV Activity”) as measured according to an HIV-1 infectivity assay that measures the extent of HIV-l replication.

IPSCIO Record ID: 28073

License Grant
The Canadian University hereby grants to the Canadian Licensee an exclusive world-wide license, in respect of the Type I Technology and a non-exclusive world-wide license in respect of the Type II Technology, to make use of, or caused to be used, sell and/or sublicense the Technology and any know how associated therewith or which forms a basis thereof whether it is the Scientist's know how, and to manufacture, commercialize, distribute, market, import, export, offer to sell, sell, lease and/or license or sublicense Products on the terms and conditions hereinafter set forth (the License).
License Property
The Scientist of  the University has been engaged in research during the course of which he has developed certain recombinant viral antigens, murine antibody clones and an animal model.

Type I Technology shall mean the recombinant viral antigens and murine antibody clones and Type II Technology shall mean the animal model.

1. Antigens cloned, expressed and purified in the Tyrrell University laboratory as follows

·
Human Hepatitis B(HBV) Core Antigen (short)

·
Duck Hepatitis B(DHBV) Surface Antigen

·
Duck Hepatitis B(DHBV) Polymerase Protein

·
Duck Hepatitis B(DHBV) Core Protein

2. Murine antibody clones developed in the Tyrrell University laboratory as follows

·
Monoclonal Antibody 1D12 to HBV core antigen

·
Monoclonal antibodies 2C12, 2D12, 2C11, 2A12, 4A10, 1F9, 2G11 to HBV surface antigen

·
Monoclonal Antibody 3A8, 2C4 to HBV Polymerase

·
Monoclonal Antibody 1F4 to DHBV Surface Antigen

·
Monoclonal Antibodies 9A8, 8D6, 7G4, 7G5, 7G10, 9F2, 9G8, 1A9, 4A9, 1H5 to DHBV Core Antigen.

3. Animal model as follows

·
Hepatitis B Duck Model

Including any replications of progeny of the above made by the Licensee and, if that which is made by the Licensee, constitutes cells or DNA molecules. Type II Technology includes all modifications, improvements and variants thereof and any data or information in relating thereto including sequence information.

Field of Use
Licensee will be commercializing novel therapeutic approaches to treat diseases, excluding cancer, in humans created by identifiable microbial pathogens.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.